|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||





* Department of Dermatology and
Section of Immunobiology, Yale University School of Medicine, New Haven, CT 06520; and
Medical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom
Th2 responses are clearly involved in the pathogenesis of atopic disease. Thus, understanding the factors responsible for Th2 sensitization at sites of allergen exposure, such as airway and skin, is crucial for directing therapeutic or preventive strategies. Contrary to other models of Th2 sensitization to proteins, we have reported that Th2 responses induced by epicutaneous exposure to OVA are IL-4 independent. Combined deficiency of both IL-4 and IL-13 signaling did prevent Th2 generation, suggesting that IL-13 was mediating these IL-4-independent responses. It was not clear, however, whether IL-13 was simply replacing the need for IL-4 in genetically deficient mice or if IL-13 played a unique role. In the present study, we show that Th2 responses induced by epicutaneous OVA exposure (including lung inflammatory responses after inhaled Ag challenge, OVA-specific IgG1, and draining lymph node IL-5 production) are impaired in IL-13-deficient (IL-13-/-) mice compared with wild type. In contrast, i.p. sensitization of IL-13-/- mice resulted in responses equivalent to wild type. Generation of contact hypersensitivity to dinitrofluorobenzene, which involves Th1 and CD8+ effector cells, was also intact in IL-13-/- mice. Taken together, the data indicate that IL-13 is the major inducer of Th2 generation in the cutaneous microenvironment, being required independently of IL-4. This fact, in combination with the known abundance of IL-13 in atopic dermatitis skin lesions, emphasizes the potentially important role of the skin as a site for Th2 sensitization to environmental allergens, particularly in atopic individuals.
This article has been cited by other articles:
![]() |
Y. Morioka, K. Yamasaki, D. Leung, and R. L. Gallo Cathelicidin Antimicrobial Peptides Inhibit Hyaluronan-Induced Cytokine Release and Modulate Chronic Allergic Dermatitis J. Immunol., September 15, 2008; 181(6): 3915 - 3922. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. L. Martin, D. Fisher, W. Glass, K. O'Neil, A. Das, E. C. Martin, and L. Li Preclinical Safety and Pharmacology of an Anti-Human Interleukin-13 Monoclonal Antibody in Normal Macaques and in Macaques with Allergic Asthma International Journal of Toxicology, September 1, 2008; 27(5): 351 - 358. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-Y. Nam, Y.-H. Kim, J.-S. Do, Y.-H. Choi, H.-J. Seo, H.-K. Yi, P.-H. Hwang, C.-H. Song, H.-K. Lee, J.-S. Kim, et al. CD30 supports lung inflammation Int. Immunol., February 1, 2008; 20(2): 177 - 184. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Muller, W. Stenzel, G. Kohler, C. Werner, T. Polte, G. Hansen, N. Schutze, R. K. Straubinger, M. Blessing, A. N. J. McKenzie, et al. IL-13 Induces Disease-Promoting Type 2 Cytokines, Alternatively Activated Macrophages and Allergic Inflammation during Pulmonary Infection of Mice with Cryptococcus neoformans J. Immunol., October 15, 2007; 179(8): 5367 - 5377. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Kalomenidis, Y. Guo, R. S. Peebles, K. B. Lane, S. Papiris, J. Elias, and R. W. Light Pneumothorax-Associated Pleural Eosinophilia in Mice Is Interleukin-5 but Not Interleukin-13 Dependent Chest, October 1, 2005; 128(4): 2978 - 2983. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Padilla, E. Daley, A. Chow, K. Robinson, K. Parthasarathi, A. N. J. McKenzie, T. Tschernig, V. P. Kurup, D. D. Donaldson, and G. Grunig IL-13 Regulates the Immune Response to Inhaled Antigens J. Immunol., June 15, 2005; 174(12): 8097 - 8105. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Kouriba, C. Chevillard, J. H. Bream, L. Argiro, H. Dessein, V. Arnaud, L. Sangare, A. Dabo, A. H. Beavogui, C. Arama, et al. Analysis of the 5q31-q33 Locus Shows an Association between IL13-1055C/T IL-13-591A/G Polymorphisms and Schistosoma haematobium Infections J. Immunol., May 15, 2005; 174(10): 6274 - 6281. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Aurelian Herpes Simplex Virus Type 2 Vaccines: New Ground for Optimism? Clin. Vaccine Immunol., May 1, 2004; 11(3): 437 - 445. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |